| 53.04 0.18 (0.34%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 62.42  |
1-year : | 72.91 |
| Resists | First : | 53.45 |
Second : | 62.42 |
| Pivot price | 51.06 |
|||
| Supports | First : | 50.43 |
Second : | 48.56 |
| MAs | MA(5) : | 51.79 |
MA(20) : | 50.96 |
| MA(100) : | 53.68 |
MA(250) : | 46.69 |
|
| MACD | MACD : | 0 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 85.8 |
D(3) : | 78.5 |
| RSI | RSI(14): 59.7 |
|||
| 52-week | High : | 60.65 | Low : | 34.16 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GSK ] has closed below upper band by 4.5%. Bollinger Bands are 35.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 53.52 - 53.74 | 53.74 - 53.94 |
| Low: | 52.35 - 52.59 | 52.59 - 52.82 |
| Close: | 52.66 - 53.03 | 53.03 - 53.39 |
GSK plc, a global pharmaceutical entity founded in 1715 and headquartered in Brentford, United Kingdom, dedicates its efforts to the research, development, and manufacturing of a wide array of medical solutions. Until May 2022, the company was known as GlaxoSmithKline plc. Its primary objective is to prevent and treat illnesses by producing both vaccines and a comprehensive range of specialty and general medicines for markets across the United Kingdom, the United States, and internationally. The company's operations are organized into two key divisions: Commercial Operations and Total R&D. Its extensive vaccine portfolio includes immunizations against shingles, meningitis, respiratory syncytial virus (RSV), seasonal and pandemic influenza, and polio. Beyond preventative care, GSK provides diverse therapeutic products covering critical areas such as HIV, oncology, respiratory and immunology conditions, and other specialized medical fields. This also encompasses inhaled treatments for chronic respiratory ailments like asthma and chronic obstructive pulmonary disease (COPD), along with antibiotics for various infections. Innovation at GSK is frequently driven by strategic partnerships. Notable collaborations include an agreement with CureVac to advance mRNA-based influenza vaccines, and alliances with Wave Life Sciences and Elsie Biotechnologies focused on developing oligonucleotide platforms. Furthermore, GSK has established two distinct strategic collaborations with Relation to progress therapeutics for fibrotic diseases and osteoarthritis. The company is also engaged in a multi-target strategic alliance aimed at developing pioneering treatments for individuals suffering from Parkinson's disease, and a partnership with Flagship Pioneering to identify novel medicines and vaccines.
Sat, 13 Jun 2026
Luke Miels, the quiet GSK boss making a $10.6bn bet on cancer - Financial Times
Fri, 12 Jun 2026
GSK's Momelotinib Pursues Rare VEXAS Syndrome Indication - PharmTech.com
Thu, 11 Jun 2026
Is GSK PLC (GSK) Overvalued After 3.3% Rally? GF Value Says Over - GuruFocus
Thu, 11 Jun 2026
GSK (GSK) leaders receive shares under employee reward plan - Stock Titan
Thu, 11 Jun 2026
GSK Strikes $10.6 Billion Deal for Nuvalent in One of Pharma's Biggest Oncology Acquisitions of 2026 - CHEManager
Wed, 10 Jun 2026
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion, FT reports - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 2,010 (M) |
| Shares Float | 3,890 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 18.7 (%) |
| Shares Short | 13,570 (K) |
| Shares Short P.Month | 15,450 (K) |
| EPS | 3.8 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.94 |
| Profit Margin | 17.7 % |
| Operating Margin | 36.2 % |
| Return on Assets (ttm) | 10 % |
| Return on Equity (ttm) | 40.9 % |
| Qtrly Rev. Growth | 1.5 % |
| Gross Profit (p.s.) | 11.88 |
| Sales Per Share | 16.3 |
| EBITDA (p.s.) | 5.68 |
| Qtrly Earnings Growth | 8.3 % |
| Operating Cash Flow | 7,740 (M) |
| Levered Free Cash Flow | 3,020 (M) |
| PE Ratio | 13.92 |
| PEG Ratio | 9.8 |
| Price to Book value | 4.43 |
| Price to Sales | 3.25 |
| Price to Cash Flow | 13.77 |
| Dividend | 0.46 |
| Forward Dividend | 0 |
| Dividend Yield | 0.8% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|